Innovent Announces Second New Drug Application of DOVBLERON was Approved by China's National Medical Products Administration
January 03, 2025 | 07:00
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases.
Mobile Version